Charisse Winecki, head of the U.S. general market at Genomma Lab, sees an opportunity for Bufferin to gain market share among consumers. She talked about the reintroduction of the brand into the ...

MEXICO CITY, June 4, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) ("Genomma Lab" or "the Company"), one of the leading pharmaceutical and personal care product companies ...

Genomma Lab Internacional SAB de CV (GNMLF) recently announced a dividend of $0.2 per share, payable on 2023-12-27, with the ex-dividend date set for 2023-12-22. As investors look forward to this ...

HOUSTON--(BUSINESS WIRE)--As consumers continue to adapt their behaviors due to the COVID-19 pandemic, offering quality and known products that can help them with their day-to-day life in the “new ...

Like-for-like ("LFL") sales: when adjusted into constant currency and excluding the hyperinflationary subsidiary, sales increased by 9.7% reflecting a double-digit increase in six out of nine core ...

Genomma Lab Internacional, S.A.B. de C.V. is one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence. Genomma Lab develops, sells and ...

Agreement Combines Procaps Oral Delivery System Technology and Manufacturing with Genomma’s Strategic Marketing and Distribution Footprint “We’re excited to partner with Genomma, as this collaboration ...

MEXICO CITY, Oct. 22, 2025 /PRNewswire/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the third quarter of 2025. All figures ...

Genomma Lab Int (LABB) has delivered a -24.340% change over the past year, with a 52-week range between 14.240 and 23.600. What Is the Average Daily Trading Volume of Genomma Lab Int (LABB)? The ...

Net sales: 6.4% increase reflecting healthy growth across regions, sales recovery in Argentina and a favorable FX environment for Genomma's ex-Mexico operations. 78% of sales grew above inflation and ...

Net sales: +5.0% increase reflecting strong Suerox sales growth across markets, primarily offset by a weaker-than-expected flu season and related market share loss of Genomma cough & cold brands in ...

(2) EBITDA defined as operating income before depreciation and amortization Net Sales: Like-for-like sales declined -3.9%, reflecting weak consumption in Mexico and disruptions in the U.S. Hispanic ...